胰腺导管癌中血管生成、细胞增殖指数、DNA倍性检测的临床意义

目的:探讨血管生成、细胞增殖指数、DNA倍性在胰腺导管癌发生、发展中的作用及临床意义。方法:对29例胰腺导管癌和7例慢性胰腺炎患者的石蜡包埋标本作苏木精鄄伊红(HE)染色,CD34、Ki67免疫组织化学染色,镜下计算微血管密度(MVD)及Ki67阳性细胞比例,同时用流式细胞仪(FCM)检测细胞核DNA倍性,计算异倍体出现率及S期比例,并结合临床病理资料对各项指标作相关分析。结果:胰腺导管癌和慢性胰腺炎都有较多的新生血管。MVD值在胰腺导管癌高、中、低分化3组之间差异无显著性。按肿瘤直径分为≤1.5cm、1.6～2.9cm、≥3cm3组,此3组间MVD值、Ki67阳性细胞百分率、DNA异倍体出现率及肿瘤周围有无浸润的差异都非常显著(P<0.01)。肿瘤越大,MVD值、Ki67阳性细胞百分率及DNA异倍体出现率越高。结论:胰腺导管癌的发生、发展伴血管生成和DNA合成增加,联合测定MVD、Ki67阳性细胞百分率、DNA倍型可能为胰腺导管癌临床预后预测提供辅助参考指标。     

带浅静脉干逆行皮瓣早期微血管构筑变化的体视学研究

目的 探讨带浅静脉干的逆行皮瓣早期微血管构筑变化的特点以供临床实践参考。方法 应用生物体视学技术测量带浅静脉干皮瓣微血管体积密度，结合组织学观察，与不带静脉干皮瓣作对照比较。结果 带浅静脉干皮瓣组微血管密度整体水平高于不带静脉干皮瓣组（P〈0．05）。结论 浅静脉干的存在有利于皮瓣的血管化进程，保留浅静脉干对皮瓣成活有利。     

肥胖者骨密度与体重及其他体成分关系的研究

目的肥胖易伴发多种慢性疾病。本文探讨肥胖者体重与体成份(脂肪、肌肉)之间的关系及其对临床减重的意义。方法经临床确诊系单纯性肥胖者45例,男17例,女28例。使用美国LunarDPX-L型双能X线吸收测量仪(DXA),测量全身骨、第2~4腰椎、股骨颈骨矿密度(BMD)及体脂肪和肌肉量,并计算体重指数(BMI=W/H2)、体重(kg)/身高(m)即W/H数值进行比较分析。结果男性体重平均94.54±17.41kg,BMI33±4.87。女性体重平均124.37±14.0kg,BMI35.41±6.39。男女两性全身BMD与体重相关,分别为r=0.415,P<0.05,r=0.529,P<0.0025。女性体重与脂肪、肌肉之间呈正相关分别为r=0.522,P<0.0025、r=0.612,P<0.005。男性体重与BMI、W/H及全身肌肉量相关,与脂肪组织无明显相关。男女性W/H较BMI相关系数高。男性全身BMD与全身肌肉量正相关r=0.421,P<0.05。女性全身及股骨颈BMD与脂肪量相关r=0.360,P<0.05、r=0.323,P<0.05。女性全身肌肉量与股骨颈BMD呈正相关r=0.373,P<0.05。结论①肥胖者体重增加,男性以肌肉增加为主,女性脂肪和肌肉都增加;②男性全身骨密度增高与肌肉量增加有关,而女性则主要为脂肪量增加;③女性肌肉、脂肪量与股骨颈BMD密切相关;④体重(kg)/身高(m)比计算体重指数能更准确地反映总体肥胖的程度。     

Relationship between insulin-like growth factor I, dehydroepiandrosterone sulfate and proresorptive cytokines and bone density in cystic fibrosis

Introduction Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA) and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1β, tumor necrosis factor α, and interleukin-6. Methods We studied 32 outpatients (18 females; mean age: 26.2 ± 7.9 years) at a tertiary care medical center. The subjects had venous samples obtained, underwent anthropometric and bone mineral density (BMD) measurements, and completed a health survey. Serum IGF-I concentrations were below the age-adjusted mean in 78% of the participants, and DHEA sulfate (DHEAS) concentrations were low in 72%. Serum concentrations of all cytokines were on the low side of normal; nonetheless, there was a modest inverse correlation between IL-1β and BMD at all sites. Results In univariate analyses, IGF-I and DHEAS were significant correlates of BMD or bone mineral content. In final multivariate models controlling for anthropometric and other variables of relevance to bone density, only IGF-I was identified as a significant independent skeletal predictor. While alterations in DHEAS, IGF-I, and specific cytokines may contribute to skeletal deficits in patients with CF, of these factors a low IGF-I concentration appears to be most strongly correlated with BMD. Conclusions These findings may have therapeutic implications for enhancing bone density in these patients.     

老年女性2型糖尿病肾病的骨密度及相关因素分析

2型糖尿病(T2DM)和骨质疏松症的发病率越来越高,它们之间有无关系越来越引起人们的重视,本研究探讨了老年女性2型糖尿病肾病(DN)的骨矿物质密度(BMD)变化与相关因素,报道如下。1对象与方法1.1研究对象按1999年WHO诊断标准确诊为T2DM的≥60岁女性114例,年龄60～75岁,平均(66.3±     

Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women

Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause. Received: 12 September 2001 / Accepted: 11 December 2001     

Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study

This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53 years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800 mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of 2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening, and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were −3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to 4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5% in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective, placebo-controlled trials. Received: 4 March 2002 / Accepted: 9 July 2002     

183例老年人骨密度检测分析

目的 :研究老年人不同疾病时骨密度 (BMD)的分布情况。方法 :用DXADAS 6 0 0EX型骨密度仪对183例老年患者进行左侧远程桡骨加尺骨BMD检测。结果 :内分泌疾病组、消化道疾病组和其它疾病组的患病率分别为 72 7% ,2 0 6 %和 31 4 %。T值比较 :三组差异明显 (P <0 0 0 1)。累积骨丢失率 (ABLR)比较 :前一组明显高于后两组病人 (P <0 0 1)。BMD比较中 ,内分泌和其它疾病组明显低于消化道疾病组 (P <0 0 0 1)。相关分析显示 ,内分泌和消化道疾病组的年龄变化与BMD呈正相关 (r =0 5 19P <0 0 0 1和r =0 5 89P <0 0 0 1) ,内分泌疾病组和其它疾病组的体重变化与BMD呈正相关 (r=0 918P <0 0 0 1和r =0 338P <0 0 0 1)。结论 :老年人骨质疏松 (OP)患病率以内分泌疾病组最高 ,消化道疾病组较低 ;随年龄和体重增加 ,BMD降低加重。     

单能量X线测定骨密度的初步分析

目的：了解温州地区人群不同年龄组骨质疏松患病率及同年龄组男女骨质疏松患病的差异，强调早期预防治疗老年人及绝经期妇女骨质疏松的重要性，方法：应用单能量X线（SXA）骨密度仪测量246例正常人的右跟骨骨密度，结果：男性大于60岁组较小于60岁组骨密度（BMD）降低明显（P＜0．05）；女性50岁以上组与小于50岁组相比，BMD下降差异有极显性（P＜0．01）；各年龄组男女相比，男性BMD明显高于女性（P＜0．05）。结论：女性骨质疏松症的发病大多以绝经后为主，雌激素在维持骨量方面具有重要的作用。SXA检测的跟骨含95％小梁骨，能较好地确定骨质疏松的风险水平，且其具有价廉、简便，快捷，较准确等特点，故不失为一种较好的临床筛查手段。